(3 minutes read)
· German Pharmaceutical company –BioNTech- which developed a coronavirus vaccine in collaboration with US pharmaceutical giant –Pfizer- in record time, is reported to be in the fast track to develop a malaria vaccine by next year
· Believed to be a game-changer against many diseases, the vaccine provokes an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells
· The Africa Centers for Disease Control and Prevention as well as the EU and the World Health Organization are focusing on the elimination of Malaria, particularly from the African continent, since the disease causes considerable social and economic costs
German Pharmaceutical company –BioNTech- which developed a coronavirus vaccine in collaboration with US pharmaceutical giant –Pfizer- in record time, is reported to be in the fast track to develop a malaria vaccine by next year.
The vaccine based on the mRNA technology same as that of Covid-19 vaccines. This will help fight the mosquito-borne diseases including malaria., which kill more than 400,000 people every year, mainly young children in Africa.
Believed to be a game-changer against many diseases, the vaccine provokes an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, People vaccinated will develop immunity faster than traditional vaccines. The Africa Centers for Disease Control and Prevention as well as the EU and the World Health Organization are focusing on the elimination of Malaria, particularly from the African continent, since the disease causes considerable social and economic costs.
BioNTech is looking at setting up an mRNA hub in Africa. The fight against Malaria received a boost in April this year. Researchers from Britain’s Oxford University announced that their Matrix-M vaccine candidate had become the first to surpass the WHO’s threshold of 75-percent efficacy, which is billed as a major breakthrough.
